8-K: InnovAge Announces Fiscal Third Quarter 2025 Financial Results, Showing Revenue Growth and Improved Adjusted EBITDA

InnovAge reports a 13% increase in revenue and a significant rise in Adjusted EBITDA for the third fiscal quarter ended March 31, 2025, driven by topline growth and cost management.

Summary

• InnovAge Holding Corp. announced its financial results for the third fiscal quarter ended March 31, 2025.
• Total revenue increased by approximately 13.0% to $218.1 million, compared to $193.1 million in the same quarter of the previous year.
• The company reported a net loss of $11.1 million, compared to a net loss of $6.2 million in the third quarter of fiscal year 2024.
• Adjusted EBITDA increased to $10.8 million, a $7.8 million increase from the $3.0 million reported in the third quarter of fiscal year 2024.
• The Adjusted EBITDA margin improved to 4.9%, up from 1.5% in the prior year's quarter.
• Center-level Contribution Margin increased by 19.9% to $40.7 million.
• InnovAge served approximately 7,530 participants, compared to 6,820 in the third quarter of fiscal year 2024.
• The company ended the quarter with $60.5 million in cash and cash equivalents, plus $41.3 million in short-term investments, and $77.3 million in debt.
• InnovAge is confirming its full fiscal year 2025 financial guidance, projecting revenues between $815 million and $865 million and Adjusted EBITDA between $24 million and $31 million.
• Dr. Richard Feifer, InnovAge's Chief Medical Officer, departed effective April 25, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth and improved Adjusted EBITDA, but tempered by the net loss and risks associated with the macroeconomic environment and regulatory landscape.

Positives

• Revenue increased by 13.0% year-over-year, indicating strong topline growth.
• Adjusted EBITDA significantly improved, reaching $10.8 million, showcasing enhanced profitability.
• The Adjusted EBITDA margin expanded by 3.4 percentage points, reflecting improved operational efficiency.
• Center-level Contribution Margin increased by 19.9%, demonstrating better performance at the center level.
• Participant census grew to approximately 7,530, indicating successful expansion of services.
• The company is maintaining its full fiscal year 2025 financial guidance, suggesting confidence in future performance.

Negatives

• The company experienced a net loss of $11.1 million, which is higher than the $6.2 million loss in the third quarter of fiscal year 2024.
• Loss Before Income Taxes of $11.1 million increased approximately 72.6%, compared to a Loss Before Income Taxes of $6.4 million in the third quarter of fiscal year 2024
• Net loss margin of 5.1%, an increase of 1.9 percentage points compared to a net loss margin of 3.2% in the third quarter of fiscal year 2024

Risks

• The company acknowledges that actual results may differ materially from its guidance due to factors outside of its control, especially in light of the uncertain macroeconomic environment and financial market volatility.
• The company faces risks related to government audits, legal proceedings, and potential repayment obligations or penalties related to inaccurate or unsupportable information submitted to government payors.
• The company's revenues are dependent on a limited number of government payors, creating a concentration risk.
• The departure of the Chief Medical Officer, Dr. Richard Feifer, could pose a short-term challenge.

Future Outlook

InnovAge is confirming its full fiscal year 2025 financial guidance, projecting total revenues between $815 million and $865 million and Adjusted EBITDA between $24 million and $31 million.

Management Comments

• CEO Patrick Blair stated that the third quarter results reflect continued strength in topline growth, disciplined cost management, and effective medical expense control.
• Patrick Blair mentioned the company is focused on building a PACE platform that delivers better outcomes for participants, generates meaningful savings for the healthcare system, and creates long-term value for shareholders.

Industry Context

InnovAge operates in the Program of All-inclusive Care for the Elderly (PACE) sector, which focuses on providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors. The company's performance is indicative of the demand for integrated care models that aim to improve quality of care while reducing healthcare costs.

Comparison to Industry Standards

• Given the focus on PACE programs, direct comparisons are limited to other PACE providers, which are often smaller and regionally focused.
• Key competitors include companies like CareSource and Element3 Health, though their financial disclosures may not be directly comparable due to differences in business models or reporting standards.
• Industry benchmarks often revolve around metrics like participant satisfaction, healthcare utilization rates, and cost savings achieved compared to traditional fee-for-service models.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the revenue growth and improved Adjusted EBITDA, but negatively to the net loss.
• Participants should benefit from the company's focus on improving the quality of care and enabling independent living.
• Employees may experience uncertainty due to the departure of the Chief Medical Officer.

Next Steps

• The company will host a conference call to discuss the financial results.
• InnovAge will continue to focus on executing its growth strategy, including attracting new participants and opening new centers.
• The company will work to manage costs and mitigate the effects of elevated expenses.

Key Dates

Keywords

InnovAge, PACE, Financial Results, Adjusted EBITDA, Revenue, Healthcare, Seniors, Medicaid, Medicare